Oct 16, 2026 | Legal Compliance, News
The FDA may be preparing to ease restrictions on certain compounded peptides, potentially opening the door for medical spas, wellness clinics, and healthcare providers to offer treatments that have faced significant federal regulatory scrutiny in recent years. On...
Sep 2, 2026 | Legal Compliance, News, Risk Management
The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...
Sep 1, 2026 | Legal Compliance, News, State-Specific Regulations
Mississippi’s three healthcare licensing boards have put the state’s providers on notice: there is no safe harbor for offering “research-grade” peptides to patients. In a joint statement issued by the Mississippi State Board of Medical...
Aug 21, 2026 | News, Risk Management
Revance Therapeutics and Teoxane have officially announced FDA approval for RHA Redensity® Eye, expanding the Teoxane RHA® Collection into the delicate infraorbital region. The hyaluronic acid (HA) filler is specifically indicated for correcting moderate to severe...
Aug 13, 2026 | Legal Compliance, News
Eli Lilly & Co. has significantly escalated its legal campaign against the illicit trade of its investigational weight-loss drug, retatrutide. The pharmaceutical giant filed lawsuits in federal court against six U.S.-based businesses—including medical spas,...
